Evidence map›Paper›PMID 39758787›Full record

ArticleInternational cancer conference journal2025

Successful immunotherapy with ipilimumab and nivolumab in a patient with pulmonary sclerosing pneumocytoma.

Yumi Inukai-Motokura, Kiichiro Ninomiya, Takahiro Baba, Hiroki Omori, Tetsuya Takeguchi, Mari Uno, Yoshiyuki Ayada, Takehiro Tanaka, Yoshinobu Maeda, Kadoaki Ohashi

Abstract read
In one paragraph

Article in International cancer conference journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yumi Inukai-MotokuraDepartment of Allergy and Respiratory Medicine, Okayama University Hospital, Okayama, Japan.
Kiichiro NinomiyaDepartment of Allergy and Respiratory Medicine, Okayama University Hospital, Okayama, Japan.ORCID 0000-0002-2134-2865
Takahiro BabaDepartment of Allergy and Respiratory Medicine, Okayama University Hospital, Okayama, Japan.
Hiroki OmoriDepartment of Allergy and Respiratory Medicine, Okayama University Hospital, Okayama, Japan.
Tetsuya TakeguchiDepartment of Allergy and Respiratory Medicine, Okayama University Hospital, Okayama, Japan.
Mari UnoDepartment of Allergy and Respiratory Medicine, Okayama University Hospital, Okayama, Japan.
Yoshiyuki AyadaDepartment of Pathology, Okayama University Hospital, Okayama, Japan.
Takehiro TanakaDepartment of Pathology and Oncology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan.
Yoshinobu MaedaDepartment of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
Kadoaki OhashiDepartment of Allergy and Respiratory Medicine, Okayama University Hospital, Okayama, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pulmonary sclerosing pneumocytoma (PSP) is a rare form of lung cancer that occasionally presents with lymph node and extrapulmonary metastases, and multiple lesions. The treatment of metastatic PSP remains undefined. This study reports the case of a 48-year-old female patient diagnosed with PSP following surgical intervention for a solitary nodule in the left lower lobe. Four years later, recurrence occurred in the left hilar and mediastinal lymph nodes, necessitating an additional resection. Concurrently, sacral metastases developed and required palliative radiotherapy. Genetic analysis identified an

Indexed as

Case reportIpilimumabNivolumabProgrammed cell death ligand 1Pulmonary sclerosing pneumocytoma

Identifiers

PMID39758787
PMCPMC11695534

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.